This article is more than 5 years old. Information may no longer be current.
TREAT
Trial to Reduce CV Events with Aranesp Therapy
Trial assessed eff ects of darbepoetin alfa vs. placebo for reduction in composite of death, MI, unstable angina, HF or stroke in patients with type 2 diabetes, chronic kidney disease and concomitant anemia.
Design: randomized, placebo-controlled
Patients: 4,038
Centers: 634
Countries: 24
RESULTS: The composite endpoint of death, MI, myocardial ischemia, HF and stroke was similar in the darbepoetin alfa group (n=2,012) vs. placebo (n=2,026; 31.4% vs. 29.7%; HR=1.05; 95% CI, 0.94-1.17). Component endpoints were also similar between the two groups, including death (20.5% vs. 19.5%, P=.48), HF (10.2% vs. 11.3%, P=.24), MI (6.2% vs. 6.4%, P=.73) and myocardial ischemia (2.0% vs. 2.4%, P=.40). For the component endpoint of stroke, there was an increase in the darbepoetin group vs. placebo (5.0% vs. 2.6%, P<.001). There was no difference in the composite renal endpoint (32.4% darbepoetin vs. 30.5% placebo, P=.29) and there was no difference in end-stage renal disease (16.8% vs. 16.3%, P=.83).
Presented at AHA 2009.
Click here to read more about the TREAT trial.